OncoQuest, Inc. (OncoQuest)

Oncology Corporate Profile

Stock Performance


HQ Location

8123 Roper Road NW
Edmonton, Alberta T6E 6S4

Company Description

OncoQuest, Inc. is a privately held, Canadian based pharmaceutical company focused on the development and commercialization of immunotherapies for cancer. OncoQuest’s technology platform includes a panel of tumor antigen specific monoclonal immunoglobulins including CA125, MUC1, PSA and Her2/neu; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. OncoQuest’s lead product is oregovomab for the treatment of ovarian cancer that is currently undergoing multiple phase 2 clinical trials. OncoQuest’s MUC1 program has already undergone a Phase 1 clinical trial in breast cancer patients, and its development is being led by OncoVent Co. Ltd., OncoQuest’s joint venture partner who has licensed the rights of the immunotherapy technologies in the territory of Greater China. OncoQuest’s next-generation products are based on immunoglobulin E licensed from UCLA, Stanford University and Advanced Immune Therapeutics, Inc. These antigen-specific monoclonal IgE antibodies are currently in preclinical development.

Website: http://oncoquestinc.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
oregovomabimmunotherapyOvarian cancerII
oregovomab (+ Hiltonol®)immunotherapyOvarian cancerI
anti-MUC1 AR20.5immunotherapyPancreatic cancerI
oregovomabimmunotherapyPancreatic cancerI

View additional information on product candidates here »

Source: http://oncoquestinc.com/Contact-Us

Recent News Headlines

There are no news items to display